Observation Treatment Group for Enterobacteriaceae Infections

"There is ample clinical data to prove this treatment's safety, granting it a rating of 3 on our scale. As the trial has reached Phase 4, the medication has been given regulatory approval."

"Data from clinicaltrials.gov confirms that this medical trial is presently enrolling participants, with the initial post date of June 7th 2021 and most recent update on June 16th 2022."

"This study, with a 30 day evaluation period, seeks to assess Clinical success across infected sites. Secondary goals include determining Total Length of hospital stays (measured in Days of hospitalization for CRE infection), 90 day Mortality (measurement being Survival at 90 days) and Recurrence of infection (calculated as Recurrence of CRE-containing infection within 90 days)."

"Yes, indeed. According to the clinicaltrials.gov data, this study is currently accepting participants and was first added on June 7th 2021. The trial requires 15 patients from one medical facility for successful completion of its protocol."

"Presently, there are 6 ongoing trials of this drug in 5 cities and 9 nations. In 2011, Pfizer funded the initial investigation which included 60 individuals that completed Phase 4 clinical approval. Since then, a total of 35 studies have been carried out."

"This treatment regimen is largely used to address endocarditis caused by staphylococcus aureus, yet it can be utilized in some cases of pyelonephritis, abdominal infection and urinary tract infections."